Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes
Interventions
DRUGrepaglinide
DRUGmetformin
DRUGglicazide
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes for at least 3 months * No previous treatment for diabetes * HbA1c between 7.0-12.0% * Body Mass Index (BMI) between 19.0-40.0 kg/m2
Exclusion criteria
* Type 1 diabetes * Known unstable/untreated proliferative retinopathy * Uncontrolled treated/untreated hypertension * Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c | after 16 weeks of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Glucose profiles | — |
| Quality of life assessment | — |
| Treatment satisfaction | — |
| Hypoglycaemic events | — |
| Adverse events | — |
Countries
China, Malaysia, Philippines, Thailand
Outcome results
None listed